Two coronavirus trials paused over safety concerns
Setback for global efforts to counter Covid as human testing of antibody treatment and vaccine put on hold
Clinical trials of a potential vaccine for Covid-19 and a treatment for people with severe cases of the disease have been put on hold because of separate safety concerns.
The treatment, produced by US drug company Eli Lilly, is “similar to one taken by US President Donald Trump this month”, says the Financial Times. It involves an infusion of “monoclonal antibodies” - artificially produced cells that mimic the human body’s natural immune response to the coronavirus.
“Ambiguity” in Eli Lilly’s statements mean the reason for the pause is unclear, but a trial may be halted if a treatment “has a very low chance of working, based on the data so far” or if “patients in one group are faring much worse than those in the other”, The New York Times reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The Eli Lilly announcement came a day after Johnson & Johnson said trials of its coronavirus vaccine were being suspended after a patient in the study fell ill.
The injection is “one of six coronavirus vaccines being tested in the US, and one of four in the most advanced, Phase 3 stage”, reports CNN.
Trials of another vaccine in the final stage of testing, developed by Oxford University and AstraZeneca, were twice put on hold due to unexplained illnesses, but have now resumed in most participating countries.
“In large clinical trials, pauses are not unusual, and declines in health in volunteers are not necessarily the result of the experimental drug or vaccine,” says The New York Times.
“Such halts are meant to allow an independent board of scientific experts to review the data and determine whether the event may have been related to the treatment or occurred by chance.”
Dr Ashish Jha of the Brown University School of Public Health told CNN that delays of this sort were “completely expected” in a trial involving 60,000 people.
Johnson & Johnson said yesterday that its team had not yet established whether the ill patient had received the potential vaccine or a placebo.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Holden Frith is The Week’s digital director. He also makes regular appearances on “The Week Unwrapped”, speaking about subjects as diverse as vaccine development and bionic bomb-sniffing locusts. He joined The Week in 2013, spending five years editing the magazine’s website. Before that, he was deputy digital editor at The Sunday Times. He has also been TheTimes.co.uk’s technology editor and the launch editor of Wired magazine’s UK website. Holden has worked in journalism for nearly two decades, having started his professional career while completing an English literature degree at Cambridge University. He followed that with a master’s degree in journalism from Northwestern University in Chicago. A keen photographer, he also writes travel features whenever he gets the chance.
-
'Good riddance to the televised presidential debate'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
Caitlin Clark the No. 1 pick in bullish WNBA Draft
Speed Read As expected, she went to the Indiana Fever
By Peter Weber, The Week US Published
-
Today's political cartoons - April 16, 2024
Cartoons Tuesday's cartoons - sleepyhead, little people, and more
By The Week US Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published
-
Long-term respiratory illness is here to stay
The Explainer Covid is not the only disease with a long version
By Devika Rao, The Week US Published
-
Covid inquiry: the most important questions for Boris Johnson
Talking Point Former PM has faced weeks of heavy criticism from former colleagues at the public hearing
By The Week Staff Published
-
China's pneumonia cases: should we be worried?
The Explainer Experts warn against pushing 'pandemic panic button' following outbreak of respiratory illness
By Keumars Afifi-Sabet, The Week UK Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published